Statistically, depression affects more than 300 million people worldwide now, nearly half of whom live in Southeast Asia and the Western Pacific, including India and China.
By 2017, more than 54 million people in China were suffering from depression. Depression causes direct or indirect economic losses of nearly 64 billion yuan every year in China.
According to the WTO, nearly 1 billion people worldwide shall have mental health problems after the COVID-19.
Hyperhomocysteinemia (HHcy) is an important potential risk factor for cardiovascular and cerebrovascular disease, depression, senile dementia and other diseases.
Hcy has a direct toxic effect on n-methyl-D-aspartic glutamate receptors in the central nervous system. Dietary management with L-Methylfolate may be effective in reducing elevated homocysteine levels and reduce direct toxic and side effects on the nervous system.
Hcy has a direct toxic effect on n-methyl-D-aspartic glutamate receptors in the central nervous system. Dietary management with L-Methylfolate may be effective in reducing elevated homocysteine levels and reduce direct toxic and side effects on the nervous system.
A clinical study of L-Methylfolate for antidepressants conducted by ALFASIGMA in US has demonstrated the benefit of a daily supplement of 15mg of LMF for patients with and without SSRI partial response and major depression. 50% among patients who were given LMF at 15mg/day had a reduction in depressive symptoms within 30 days. 84% had a significantly relieved.
In the USA, our partner Methyl-Life™ is honored to have been the first company offer this uniquely superior form of L-Methylfolate to the customer over 5 years. https://methyl-life.com/
Recent studies show that Magnafolate® PRO significantly greater purity, stability and potency results when compared against other competing brands.
Magnafolate® PRO, proven to be the purest methylfolate on the planet.